Global Implantable Cardioverter Defibrillators (ICD) Market Size Study by Product Type (Transvenous ICDs, Subcutaneous ICDs), by Type (Single Chamber ICDs, Dual Chamber ICDs, Biventricular Devices), by NYHA Class (Class II, Class III), by End-use (Hospita

Global Implantable Cardioverter Defibrillators (ICD) Market Size Study by Product Type (Transvenous ICDs, Subcutaneous ICDs), by Type (Single Chamber ICDs, Dual Chamber ICDs, Biventricular Devices), by NYHA Class (Class II, Class III), by End-use (Hospitals, Ambulatory Surgical Centers, Others) and Regional Forecasts 2022-2032

Global Implantable Cardioverter Defibrillators (ICD) Market is valued approximately at USD 3.81 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.4% over the forecast period 2024-2032. The Implantable Cardioverter Defibrillator (ICD) represents a significant technological advancement in the field of cardiology, designed to monitor and regulate heart rhythms in patients at high risk of sudden cardiac arrest. The device is implanted under the skin, near the heart, and works by detecting dangerous arrhythmias such as ventricular tachycardia or fibrillation, and promptly delivering electrical shocks to restore a normal heart rhythm. The demand for ICDs is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) globally, which are on the rise due to factors such as aging populations, sedentary lifestyles, and other associated risk factors. These devices are crucial in the ongoing management of patients with a history of life-threatening arrhythmias or heart failure, significantly improving survival rates.

The Global ICD Market is bolstered by continuous technological advancements, including the development of MRI-compatible ICDs, devices with longer battery life, and smaller, less invasive models. These innovations not only enhance the safety and efficacy of ICDs but also increase their adoption among patients and healthcare providers. Additionally, growing awareness of sudden cardiac arrest and the critical role ICDs play in preventing these events, coupled with government initiatives aimed at reducing the burden of cardiovascular diseases, are expected to further drive market growth. These factors, combined with the expansion of healthcare infrastructure in emerging markets, present substantial opportunities for market expansion.

The Global ICD Market is also poised for growth due to the aging global population, which is a key demographic at higher risk of cardiovascular diseases. As the number of elderly individuals continues to increase, the demand for ICDs is expected to grow correspondingly. However, challenges such as the high cost of ICDs, including the expenses related to implantation procedures and follow-up care, may hinder market growth, particularly in regions with limited healthcare funding or where patients lack adequate health insurance.

North America accounted for the largest share of the global market in 2023, representing 41.4% of the total market value. The region's dominance is attributed to its advanced healthcare infrastructure, high prevalence of CVDs, and the presence of leading market players such as Medtronic, Abbott, and Boston Scientific. Medtronic's recent introduction of extravascular ICDs (EV-ICDs), which offer promising clinical efficacy in treating ventricular arrhythmias and tachycardia, highlights the region's leadership in this field. Conversely, the Asia-Pacific region is anticipated to experience the fastest growth during the forecast period, driven by the high prevalence of CVDs in countries like China, India, and Japan, alongside rapid advancements in healthcare technology.

Major market players included in this report are:

Medtronic

Boston Scientific

Abbott Laboratories

Biotronik

Philips Healthcare

Sorin Group (now part of LivaNova)

Zoll Medical Corporation

Nihon Kohden Corporation

MicroPort Scientific Corporation

LivaNova

The detailed segments and sub-segments of the market are explained below:

By Product Type:
• Transvenous Implantable Cardioverter-Defibrillators
• Subcutaneous Implantable Cardioverter Defibrillators

By Type:
• Single Chamber ICDs
• Dual Chamber ICDs
• Biventricular Devices

By NYHA Class:
• NYHA Class II
• NYHA Class III

By End-use:
• Hospitals
• Ambulatory Surgical Centers
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico
• RoLA

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.